Fig. 5From: Prognostic role of pretreatment 18F-FDG PET/CT and hematological parameters in relapsed/refractory Hodgkin lymphoma patients treated with immune checkpoint inhibitors and chemotherapy: a dual-center cohort studySUVmax ≥ 11.62, LDH ≥ 258.5 U/L and high-risk group (SUVmax ≥ 11.62 and LDH ≥ 258.5 U/L), were associated with unfavorable outcome. Kaplan–Meier analysis for PFS in the SUVmax ≥ 11.62 vs. SUVmax < 11.62 (a); LDH ≥ 258.5 U/L vs. LDH < 258.5 U/L (b); high-risk group (SUVmax ≥ 11.62 and LDH ≥ 258.5 U/L) vs. intermediate-risk group (SUVmax < 11.62 or LDH < 258.5 U/L) vs. low-risk group (SUVmax < 11.62 and LDH < 258.5 U/L) (c), respectivelyBack to article page